BridgeMD
New treatment option for Cardiorenal Syndrome
Official title Exercise Rehabilitation for Cardiorenal Syndrome in HFrEF Patients
ClinicalTrials.gov ID: NCT07167368
What this study is testing
What is Standardized Basic Drug Therapy for HFrEF with Chronic Kidney Dysfunction?
Standardized Basic Drug Therapy for HFrEF with Chronic Kidney Dysfunction is an investigational medicine, given as an once-weekly, being studied as a potential treatment for cardiorenal syndrome.
Also referred to as Guideline-Based Basic Medication Regimen for CRS Patients with HFrEF.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to investigate the efficacy and safety of exercise rehabilitation in patients with cardiorenal syndrome (CRS). Building on previous research demonstrating that exercise rehabilitation can effectively improve cardiac function and cardiopulmonary endurance in patients with chronic heart failure, this study will further explore its role in the context of CRS, a condition where such effects remain understudied.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Patients with chronically stable HFrEF complicated by kidney dysfunction (eGFR \< 90 mL/min/1.73m²)
- NYHA class II-III
- Low risk in exercise risk assessment
- Aged 18-75 years
You likely can't join if
- Uncontrolled hypertension
- Severe arrhythmias (including frequent ventricular premature contractions, ventricular tachycardia, rapid atrial fibrillation, sick sinus syndrome...
- Obstructive hypertrophic cardiomyopathy
- Moderate to severe stenotic valvular heart disease
- Deep vein thrombosis or pulmonary embolism
- History of syncope
See the full eligibility criteria
- Patients with chronically stable HFrEF complicated by kidney dysfunction (eGFR \< 90 mL/min/1.73m²)
- NYHA class II-III
- Low risk in exercise risk assessment
- Aged 18-75 years
- Uncontrolled hypertension
- Severe arrhythmias (including frequent ventricular premature contractions, ventricular tachycardia, rapid atrial fibrillation, sick sinus syndrome, and second-degree or higher atrioventricular block)
- Obstructive hypertrophic cardiomyopathy
- Moderate to severe stenotic valvular heart disease
- Deep vein thrombosis or pulmonary embolism
- History of syncope
- Severe anemia
- Abnormal thyroid function
- Severe pulmonary diseases
- Mental illnesses
- Osteoarticular or muscular diseases that impede rehabilitation training
The study team makes the final eligibility decision.
Where it's taking place
- Nantong, Jiangsu, China
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nantong, Jiangsu, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.